



Hypoxic Signalling in Tumour Stroma

Anu Laitala and Janine T. Erler*

Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), Copenhagen, Denmark

Hypoxia is a common feature in solid tumors and is associated with cancer progression. The main regulators of the hypoxic response are hypoxia-inducible transcription factors (HIFs) that guide the cellular adaptation to hypoxia by gene activation. The actual oxygen sensing is performed by HIF prolyl hydroxylases (PHDs) that under normoxic conditions mark the HIF- α subunit for degradation. Cancer progression is not regulated only by the cancer cells themselves but also by the whole tumor microenvironment, which consists of cellular and extracellular components. Hypoxic conditions also affect the stromal compartment, where stromal cells are in close contact with the cancer cells. The important function of HIF in cancer cells has been shown by many animal models and described in hundreds of reviews, but less is known about PHDs and even less PHDs in stromal cells. Here, we review hypoxic signaling in tumors, mainly in the tumor stroma, with a focus on HIFs and PHDs.

OPEN ACCESS

Edited by:

Giuseppe Filomeni,
Danish Cancer Society,
Denmark

Reviewed by:

Kasper Rouschop,
Maastricht University,
Netherlands
Simone Cardaci,
University of Glasgow,
United Kingdom

*Correspondence:

Janine T. Erler
janine.erler@bric.ku.dk

Specialty section:

This article was submitted
to Molecular
and Cellular Oncology,
a section of the journal
Frontiers in Oncology

Received: 14 February 2018

Accepted: 14 May 2018

Published: 29 May 2018

Citation:

Laitala A and Erler JT (2018)
Hypoxic Signalling in
Tumour Stroma.
Front. Oncol. 8:189.
doi: 10.3389/fonc.2018.00189

Keywords: hypoxia, HIF, PHDs, tumour stroma, metastasis

INTRODUCTION

Solid tumors are most often partly hypoxic. During the rapid growth of cancer cells, the surrounding vasculature becomes inadequate and is unable to meet the high demand of oxygen creating heterogeneously distributed hypoxic areas within the tumor. Hypoxia in tumors promotes abnormal angiogenesis, desmoplasia, and inflammation. It also boosts the selection of cancer cells that have a more malignant phenotype promoting tumor progression and metastasis, and thereby serving as an indicator for disease outcome. Hypoxic tumor cells are also resistant to radiotherapy and most chemotherapies. Tumors include stromal cells and extracellular matrix (ECM) in addition to cancer cells, which are also affected by the hypoxic environment (1, 2). An ever-increasing number of studies have highlighted the importance of the tumor microenvironment (TME) in regulating tumor progression and dissemination (3).

The cellular response to the drop in oxygen concentration leads to stabilization of hypoxia-inducible transcription factor (HIF) in all cell types, which is one of the key regulators of hypoxia response. The HIF prolyl hydroxylases (PHDs) are oxygen-dependent enzymes that target HIF for degradation in air. Thus, in hypoxia, PHDs are inactive, and HIF is stabilized. HIF regulates the expression of many genes that help cells to adapt to hypoxic conditions by decreasing oxygen consumption and increasing its supply. Generally, this includes shifting the energy metabolism to the less oxygen requiring glycolytic pathway and stimulation of the angiogenic genes to increase vascular flow to the hypoxic regions (4).

In addition to HIF activation, responses to hypoxia are also mediated through HIF-independent pathways. These signaling mechanisms include the unfolded protein response (UPR) and mammalian target of rapamycin (mTOR) signaling (5). They work as independent pathways, but in many cases, their signaling is integrated with HIF activation as well as with each other (6).

Unfolded protein response is activated during endoplasmic reticulum (ER) stress. ER stress arises from accumulation of unfolded proteins, which can be contributed by several factors such

as nutrient and calcium depletion and hypoxia. It consists of different and complex signal-transduction cascades, where pancreatic ER kinase (PERK), inositol-requiring enzyme 1, and activating transcription factor 6 act as sensor proteins, situated in the ER membrane. These mediate pro-survival signaling aiming to counteract ER stress by limiting the production of unfolded proteins and degrading the misfolded proteins preventing cellular damage (5, 7). However, if UPR is not able to re-establish ER homeostasis, it can also lead to pro-death signaling leading to apoptosis. Many publications have shown UPR to be activated in numerous tumor types where hypoxia is one of the promoting factors. Cancer cells have, however, found ways to avoid the ER stress-induced apoptosis (7). UPR signaling has been shown to target vascular endothelial growth factor (VEGF) in cancer cells. Activation of transcription factor 4, which is downstream of the PERK, was shown to induce VEGF mRNA levels, but to lesser extent than HIF signaling. UPR was, nevertheless, also shown to phosphorylate HIF-1 α enhancing its activity, which resulted in increased VEGF expression (8). UPR signaling has also been shown to have a role in tumor infiltrating immune cells, which can promote both immunosurveillance and immune escape mechanisms (9).

The mTOR kinase is a part of the mTOR complexes 1 and 2 (mTORC1 and 2), and it regulates cell survival, growth, and metabolism. mTOR mediates signals from different intracellular and extracellular stimuli such as growth factors, nutrients, stress, and oxygen levels (10). As a result, mTOR is phosphorylated at multiple sites, which in turn leads to direct phosphorylation of downstream targets such as eukaryotic translation initiation factor 4E binding protein 1 and ribosomal protein S6 kinase. Many of mTOR upstream signaling pathways go through the tumor suppressor tuberous sclerosis 1 and 2 (TSC1/2) complex, and it is also subject to hypoxic regulation. TSC1/2 complex negatively regulates the small GTPase ras-homolog-enriched-in-brain (Rheb). During mTOR activating signaling, TSC1/2 complex is inhibited by phosphorylation, leading to mTOR activation through active Rheb (6, 11). Hypoxia is known to increase the ratio of AMP/ATP, which leads to activation of AMP-activated protein kinase (AMPK). AMPK is capable of phosphorylating TSC2, but this phosphorylation on the contrary activates the TSC1/2 complex, which inhibits Rheb. Inactive Rheb in turn cannot phosphorylate mTOR, which attenuates the downstream signaling (12). mTOR signaling also intercepts with HIF-dependent hypoxic signaling. HIF upregulates the expression of REDD1 (regulated in development and DNA damage responses), which also activates TSC1/2 complex decreasing mTOR signaling (13). However, this inhibitory mechanism seems to have cell type-dependent differences (14). Oncogenic mTOR has also been reported to promote HIF signaling as well as HIF target gene expression such as lysyl oxidase (LOX) (15) in an HIF-dependent way. VEGF, however, has been shown to be regulated by both HIF-dependent and HIF-independent mechanisms (16). This was also seen in cancer-associated fibroblasts (CAFs) isolated from human breast cancers where tumor suppressor p16^{INK4A} downregulation led to increased Akt/mTOR signaling also affecting HIF- α positively and further increasing the VEGF-A secretion. Enhanced Akt/mTOR signaling in CAFs was shown also to increase their

invasion and migration capabilities. However, the role of HIF was not addressed (17).


Of these three different hypoxia response pathways mentioned, we will focus on the HIF signaling pathway that influences both cancer and stromal cells. Little is known about how HIF/PHDs activities regulate stromal cell function in the TME. Here, we review how HIF/PHD pathways impact on cancer progression in the different cellular and non-cellular compartments of TME.

HIFs AND PHDs: KEY PLAYERS IN OXYGEN SENSING AND HYPOXIA SIGNALING

Hypoxic signaling is mediated *via* the hypoxia-inducible transcription factor (HIF), which is a dimer consisting of two subunits, HIF- α and HIF- β . HIF- β (also known as ARNT) is constitutively expressed and stable, but HIF- α is targeted to proteasomal degradation under normoxic conditions. Both subunits contain basic helix-loop-helix and PER-ARNT-SIM domains that are important for DNA binding and dimerization, but only HIF- α contains an oxygen-dependent degradation (ODD) domain that is important for the oxygen-dependent regulation. Under hypoxic conditions, HIF- α is able to bind with HIF- β forming a dimer that specifically binds to hypoxia response elements and so activates the transcription of over hundreds of genes that help the cells to adapt to low oxygen levels (18–21).

HIF- α has three different isoforms, HIF-1 α , HIF-2 α , and HIF-3 α , of which the two first are more widely studied. HIF-1 α and HIF-2 α resemble each other, but the main differences are in their N-terminal transactivation domain (N-TAD). They both have a similar C-terminal transactivation domain (C-TAD), which contributes to the transcription of their shared targets, whereas the N-TAD differences confer the different binding capabilities and specificity among their targets (22). HIF-3 α is the most different from the three and is subject to extensive alternative splicing resulting in many splicing variants. It has only one specific proline residue in the ODD domain and is lacking the C-TAD. Its function only as a transcription factor has been doubted and in fact different HIF-3 α variants have been shown to have inductive and suppressive effects on HIF targets (23, 24).

The ODD domain contains two specific proline residues (Pro402 and 564 in human HIF-1 α) that are hydroxylated under normoxic conditions by the HIF prolyl hydroxylase 1–3 (also known as EGLN2, 1, and 3 or HIF-P4H1-3) (**Figure 1**). These enzymes belong to the 2-oxoglutarate (2-OG)-dependent dioxygenases and require oxygen, iron, ascorbate, and 2-OG for the hydroxylation reaction. The hydroxylated prolines act as recognition sites for the von Hippel-Lindau (pVHL)–E3 ubiquitin ligase complex, which tags HIF- α for proteasomal degradation (18, 25, 26). HIF is also regulated by factor-inhibiting HIF (FIH) in normoxia. FIH belongs to the same 2-OG family as PHDs. It hydroxylates the asparagine residue within the C-TAD blocking HIF from binding to the p300-CBP coactivators and inhibits the transcriptional activation of HIF (27).



HIF prolyl hydroxylases are fast in responding to changes in O_2 concentration due to their much higher K_m values than the physiological O_2 concentrations (28). They are widely expressed in different tissues, but at varying levels. PHD2 is the main enzyme to regulate HIF. Inactivation of PHD2 alone leads to HIF stabilization in normoxia. Both PHD1 and PHD3 are generally regarded to have a complementary role as inactivation of these alone does not lead to HIF stabilization (29). Global inactivation of PHDs in mice supports the finding that PHD2 is a key modulator in HIF regulation. Inactivation of PHD2 led to embryonic lethality, whereas phenotypes resulting from PHD1 or PHD3 inactivation were viable and grossly normal (30). PHDs have specificity toward different HIF- α hydroxylations. PHD2 preferentially hydroxylates HIF-1 α , whereas PHD3 has a preference toward HIF-2 α (31). Both PHD2 and PHD3 are hypoxia inducible, and it seems PHD2 is upregulated more by HIF-1 and PHD3 by HIF-2 (32). PHD2 has been reported to bind HIF-1 α also in hypoxia inhibiting the HIF-1 α N-terminal transcriptional activity without affecting its proteolysis (33).

HIF prolyl hydroxylases have been reported to have additional targets and to participate in HIF-independent signaling. PHD2 has been shown to inhibit Akt by hydroxylation and binding of pVHL. As hypoxia inhibits PHD2, it activates and promotes tumor growth *via* Akt (34). PHD3 has been reported to interact with activating transcription factor-4, which has been shown to activate genes involved in redox balance, apoptosis, and general

cell survival under conditions of compromised nutrition (35, 36). PHD3 has been associated with apoptosis *via* different mediators. For example, PHD3 induces a neuronal regulator kinesin family member 1B β (KIF1 β) that in turn induces apoptosis. For this interaction, PHD3 hydroxylation activity was required, but it is still not known whether there is direct hydroxylation of KIF1 β (37). PHD3 has been found to hydroxylate and activate the human homolog of the *Caenorhabditis elegans* biological clock protein CLK-2 (HCLK2), which is an important player in DNA damage response. This was required for the activation of the ATR/CHK1/p53 pathway, so that inhibition of PHD3 attenuated DNA damage and the consequent apoptosis (38). PHD3 also directly inactivates the β_2 -adrenergic receptor (β_2 AR) by hydroxylating the intracellular domain, which leads to binding of the pVHL and subsequent degradation. β_2 AR activation is also known to play a role in apoptosis (39, 40).

HIF AND PHDs IN TUMORIGENESIS: BAD COPS?

Extensive literature exists regarding the role of HIF and PHDs expressed by tumor cells. We will only touch on a few aspects here, and we recommend more in-depth reviews such as Rankin et al. (41) and Schito and Semenza (4) for more detailed information. Generally, HIF activation in cancer cells has been regarded

as tumor promoting. In solid tumors, this usually results from oxygen deprivation leading to hypoxia. However, HIF signaling can also be activated by other oncogenic or tumor suppressor pathways, but mutations directly affecting HIF activation are not common in cancer, with the exception of pVHL deficiency (42). As pVHL mediates the proteolysis of HIF- α subunits, inactivation of this protein leads to constitutively active HIF also in normoxic conditions. However, Von Hippel-Lindau mutations are responsible only for a limited set of cancers such as clear cell renal cancer (ccRCC), pheochromocytoma, and pancreatic neuroendocrine tumors. HIF-2 α has been shown to be the driving force in ccRCC (43). HIF activation can also be controlled through PI3K/PTEN/AKT and RAS/RAF/MAPK signaling pathways. The former regulates the mTOR signaling that increases the translation of HIF protein, as described earlier. The latter has been reported to promote the HIF-coactivator p300 complex and subsequent transcription of target genes (42, 44, 45).

The metabolic components have also been shown to affect HIF stabilization through oxygen-independent regulation of PHD activity. The citric acid cycle (CAC) intermediate 2-OG is an absolute requirement for the enzymatic activity of PHD enzymes, whereas excess amount of other CAC metabolites fumarate, succinate, and oxaloacetate competitively inhibit PHDs (46). Inactivating mutations in enzymes processing fumarate and succinate leading to their accumulation, have been shown to induce HIF, and are associated with rare hereditary cancers, such as papillary renal cell carcinoma and paraganglioma (47–49). Mutations driving abnormal activation of isocitrate dehydrogenase (IDH) 3 α were shown to decrease 2-OG amount causing HIF stabilization in cancer cells (50). Other types of IDH mutations lead to the production of 2-hydroxyglutarate (2-HG), which can competitively inhibit PHDs or even increase the activity depending on the 2-HG stereoisomerism (51, 52). However, the mechanisms for the PHD activation by 2-HG is debated (53). In triple negative breast cancer cells, the xCT glutamate-cystine antiporter has been shown to be inhibited by increased glutamate secretion. This in turn decreases the cellular cysteine level. Free cysteine prevents the oxidation of the specific cysteine residues in PHD2, but when the level decreases it leads to self-inactivation of PHD2 and subsequent HIF stabilization (54). Cancer cell-secreted lactate from glycolysis was shown to stabilize HIF in tumor-associated macrophages (TAMs) leading to induction in VEGF and arginase 1 (ARG1), markers associated with an M2 phenotype (55).

Multiple reports have showed that HIFs in cancer cells play a role in tumor progression. Inactivation of either HIF-1 α or HIF-2 α in *in vivo* breast cancer cell models decreases tumor growth and metastasis to the axillary lymph nodes (56), lung (57–61), and bone (62, 63). Hypoxia promotes cancer cell survival in multiple different ways and these have been reviewed in many papers (64, 65). These ways include the switch to anaerobic metabolism and neovascularization, which will be discussed further below. Hypoxia also promotes growth factor signaling, epithelial–mesenchymal transition, decrease in the apoptotic potential and evasion from the immune system. Cancer cells secrete growth factors to promote their own growth and survival as they generally also have membrane receptors for these factors,

resulting in autocrine signaling. These growth factors also stimulate the surrounding stromal cells to change into a tumor promoting phenotype (65). HIF-1 has been shown to directly inhibit apoptosis by decreasing for instance the expression of the proapoptotic Bcl-2 family protein Bid (66) and to induce the expression of the apoptosis inhibitor survivin (67). In this way, cancer cells are protected from the harsh hypoxic environment leading also to a decrease in drug responsiveness (66). Hypoxia also modifies the cell surface proteins, which can shield the cells from immune system in many ways. For example, HIF-1 has been shown to directly upregulate programmed death-ligand 1 (PD-L1) (68) that suppresses T cell activation and CD47, which prevents phagocytosis by macrophages (69). HIF-1 induces a set of microRNAs that are small, non-coding RNA molecules known as hypoxamiRs (70). One of these is miR-210, which has been shown also to regulate cancer cell sensitivity toward cytotoxic T lymphocyte (CTL)-mediated lysis. miR-210 promotes cancer cell immune evasion without affecting cell surface proteins or CTL reactivity (71). In addition, HIF-induced miR-210 was shown also to promote angiogenesis. In cancer cells, miR-210 inhibits the expression and secretion of fibroblast growth factor receptor-like 1, which in turn was found to be a negative regulator of the angiogenesis (72).

In addition, hypoxia promotes cancer cell invasion and metastasis. For example, hypoxia enhances the motility and invasiveness of the cancer cells by promoting epithelial to mesenchymal transition. This happens by upregulating the expression of the transcription factors Snail1, Snail2, and Twist that downregulate expression of E-cadherin that is an important component of the adherens junctions. HIF also mediates this indirectly *via* Notch signaling (59, 73). Generally, CAFs are responsible for the remodeling of the ECM that assists in cancer cell invasion. However, numerous publications have proved that hypoxia induces cancer cells to secrete ECM remodeling enzymes that have essential roles in invasion, metastasis and premetastatic niche formation (60, 74–80). HIF-1 also mediates expression levels of angiopoietin-like 4 and L1 cell adhesion molecule. The former hampers vascular permeability and the latter cancer cell adhesion to the vasculature. Both are needed in intravasation and extravasation during the metastatic process (57).

Hypoxia also promotes the cancer stem cell phenotype. These cells are capable of unlimited cell division, differentiation to other cell types and, most importantly, can initiate cancer (59, 81). The hostile hypoxic microenvironment in the primary tumor primes the cancer cells to survive in the metastatic organ. There is some evidence that hypoxia plays a role in setting a dormancy phenotype by upregulating the main dormancy genes (NR2F1, DEC2, and p27) in breast cancer cells, which persist post-hypoxia helping the cancer cells to become therapy resistance (82).

Experiments have also been performed targeting PHDs that regulate HIF stability. Cancer cell-specific PHD2 haploinsufficiency in the MMTV-PyMT breast cancer model led to increased HIF-1 α and HIF-2 α stabilization, but that did not have an effect on tumor growth or directly on the cancer cells' invasive behavior. However, reduced lung metastasis was seen (83). In the MDA-MB-231 breast cancer model, PHD2 inactivation in cancer cells leads also to attenuate tumor growth. This

resulted from decreased transforming growth factor β (TGF- β) processing leading to decreased expression of the extracellular protein osteopontin (SPP1), which has been associated with breast cancer malignancy (84). However, opposing results have been reported with the MCF-7 breast cancer model where PHD2 inactivation in cancer cells promoted tumor growth (84, 85) by upregulation of interleukin-8 (IL-8), VEGF, and the growth factor amphiregulin leading to increased vasculature formation (85). PHD2 inactivation led to HIF-1 α stabilization and increased tumor growth in human colon carcinoma (HCT116), colorectal carcinoma (HT29 and RKO), and pancreatic carcinoma (SU.86.86) models. Generally, this was due to increased number of blood vessels. Further experiments with HCT116 cells revealed that the phenotype was not only HIF dependent. PHD2 was also shown to negatively regulate the transcription factor NF- κ B. Hence, PHD2 inactivation led to increased secretion of angiogenic factors IL-8 and angiogenin (ANG) *via* NF- κ B. These recruited bone marrow-derived cells (BMDCs) and promoted angiogenesis (86). PHD2 inactivation in murine osteosarcoma LM8, Lewis lung carcinoma (LLC), and B16BL6 melanoma cell lines also decreased tumor growth *in vivo*. The effect was claimed to be mainly HIF-independent since inactivation of HIF-1 α led to increase in the tumor growth, which could be abolished when HIF-1 α was inactivated together with PHD2. After more validation in the LM8 cell line, the PHD2 inactivation was shown to increase the number of vessels in the tumor but with decreased number of circulating cancer cells leading to reduced lung metastasis. LM8 cells were found to have increased expression of matrix metalloproteinases MMP2 and MT1MMP, which increased TGF- β signaling leading to decreased cancer cell proliferation (87, 88). PHD2 overexpression in the pancreatic cancer cells MIA PaCa-2 and PANC-1 decreased tumor growth by suppressing tumor vasculature in an HIF-dependent way resulting from decreases seen in VEGF and angiopoietin-1 (ANGPT1). However, this did not affect metastasis (89).

HIF prolyl hydroxylase 1 has been shown to play a role in cancer progression, but mainly in HIF-independent ways. PHD1 inactivation in ZR75-1, T47D, and MCF7 breast carcinoma cell lines decreased the tumor growth *in vivo* by HIF independently decreasing the cyclin D levels that are involved in cell cycling processes (90). Later PHD1 was shown to hydroxylate Forkhead box O3 (FOXO3), which hampers its interaction with the USP9x deubiquitinase leading to degradation. Decrease in FOXO3a decreases the cyclin D levels (91). Inhibition of PHD1 in HCT116 human colon carcinoma cells *in vitro* sensitized the cells for chemotherapy by decreasing p53 activation during the treatment and inhibited DNA repair increasing cell death (92).

HIF AND PHDs IN TUMOR STROMA: GOOD COPS?

It has become more evident that cancer progression is not only regulated by the cancer cells but also by the surrounding cancer stroma (93). In addition to the cancer cells, the TME includes different cells such as CAFs, endothelial cells (ECs), immune

cells, growth factors, cytokines, and ECM (94). As described earlier, HIF activation in cancer cells has generally been regarded as a tumor-promoting factor, but opposing results have been shown with stromal cells. Global PHD2 haplodeficiency leading to increased stromal HIF-1 α and HIF-2 α stabilization did not have an effect on primary tumor growth in LLC and pancreatic carcinoma tumor models as well as in the MMTV-PyMT breast cancer metastasis model. Surprisingly, PHD2 haplodeficiency led to decreased lung metastasis, and this clearly demonstrated the importance of stromal hypoxic signaling on tumor progression (83, 95). Recent publications show that stromal factors together regulate the growth and metastatic capabilities of the cancer cells in a complex manner, but nevertheless revealing possible insights into new therapeutic targets.

HYPOXIC RESPONSE OF CAFs

Cancer cells are known to harness normal quiescent fibroblast to promote cancer progression and one way they achieve this is by secreting TGF- β . This activates the fibroblasts that become CAFs with increased capacity to contract and remodel the ECM (96). CAFs are the most abundant stromal cell type and are generally thought to promote cancer progression. Many coculture experiments with CAFs and cancer cells show increased tumor growth when compared with normal fibroblast together with cancer cells (97). CAFs can promote cancer cell invasion by secreting growth factors and cytokines or remodeling the ECM—either making tracks or aligning fibrils for cancer cells to travel along (98). When fibroblasts become CAFs, their gene expression changes, and one of the most commonly used marker for CAFs is α -smooth muscle actin (α SMA). In addition to α SMA, CAFs have been shown to express other markers such as fibroblast-specific protein 1 (FSP1), platelet-derived growth factor receptor (PDGFR), fibroblast activation protein, and periostin, for example. Recently, it has become clear that CAF populations are heterogeneous with diverse markers, which may give them specific functions during tumorigenesis (99).

HIF-1 has been shown to play a role in normal fibroblast and CAF behavior. One experiment showed HIF-1 α as a tumor suppressor when its inactivation in FSP1-expressing cells in MMTV-PyMT transgenic mice led to enhanced tumor growth by reducing the tumor vascular density with less leaky vessels together with decreased infiltration of TAMs. The molecular mechanisms behind these results were not characterized. No difference was seen, however, in tumor growth in the same model with HIF-2 α -deficient fibroblasts (100). Another experiment with *in vitro* data indicated that hypoxic CAFs are involved in formation of new blood vessels in a manner requiring both HIF-1 α and G-protein estrogen receptor to upregulate VEGF in hypoxia (101). HIF-1 α has been shown to work as a tumor promoting factor as well. Experiments using the active form of HIF-1 α in human skin fibroblast showed increased tumor growth when co-injected together with MDA-MB-231 cells, whereas HIF-2 α did not have an effect. It was suggested that HIF-1 α activation led to autophagy and aerobic glycolysis, which would produce nutrients to surrounding cancer cells promoting their growth (102, 103). PHD2 modulation in CAFs also affects tumor progression, but

mainly *via* HIF. Hypoxia, PHD2 depletion, or PHD2 haplodeficiency was shown to inactivate CAFs by reducing their contraction and ECM remodeling capabilities (83, 104). Yes-associated protein 1 oncoprotein has been demonstrated to be important for CAF activation. It mediates the contraction *via* myosin light chain (MLC), which in turn regulates the contractile actomyosin function (105). Hypoxia and dimethylxalylglycine (DMOG) decreased the levels of the phosphorylated MLC in CAFs (104). CAF inactivation was further demonstrated *in vivo* when CAFs with either PHD2 haplodeficiency or shRNA inactivation were orthotopically transplanted together with breast cancer cells leading to decreased lung metastases but without any changes in primary tumor growth (83, 104). Also, systemic PHD inhibition with DMOG decreased lung and liver metastases in a 4T1 breast cancer model. DMOG treatment also reduced the stiffness and α SMA levels within the tumors without affecting the number of α SMA positive cells (104). However, PHD2 haplodeficiency in platelet-derived growth factor receptor α (BDGFR α)-positive CAFs in MMTV-PyMT transgenic mice did not have an effect on the lung metastases (83). As a side note, targeting only one CAF marker might not ensure wide inactivation in a heterogeneous CAF population (99).

HYPOXIC RESPONSE OF THE TUMOR VASCULATURE

The tumor vasculature is essential in supplying nutrients and oxygen to the fast dividing cancer cells but becomes quickly inadequate to meet the need of a fast expanding tumor. Oxygen deprivation in the tumor causes HIF stabilization and upregulation of proangiogenic factors both from cancer cells and tumor stromal cells to promote the vessel formation needed for tumor progression and metastasis (106). ECM proteins have also been shown to be involved in angiogenesis. Hypoxia-inducible LOX promotes the expression of VEGF in cancer cells *via* PDGFR β -mediated Akt activation (107). Tumor vasculature, however, has been found to be abnormal with morphological changes, leakiness, and aberrant pericytes, which result in poorly perfused vessels that are not able to rescue the hypoxic condition. This results from excessively secreted pro- and antiangiogenic factors leading to disorganized vessel formation. This can hinder, for example, the delivery of anticancer drugs and also benefit cancer cells during their extravasation process (108).

Inactivation of HIF-1 α in Tie2 positive ECs lead to decreased tumor growth in a subcutaneous LLC model, caused by reduced density of tumor vessels. ECs had decreased proliferation and migration under hypoxia as well as decreased expression levels of VEGF and VEGF receptor-1 (VEGFR-1). This demonstrated the importance of EC autocrine expression of these factors during vessel formation (109). Similar results were obtained with the MMTV-PyMT breast cancer model and the LLC model. HIF-1 α inactivation in Tie2-positive ECs drastically decreased lung metastasis, but only had moderate effect on primary tumor growth. In addition, HIF-1 α inactivation decreased the expression of inducible nitric oxide synthase (iNOS), further decreasing the amount of nitric oxide (NO) and leading to less permeable ECs for cancer cell migration. HIF-2 α inactivation

in ECs on the other hand led to decreased levels of arginase 1 (ARG1), which in turn increased the NO levels making the EC layer more accessible for cancer cells. Supporting this finding, *in vivo* tail vein injection of LLC cells showed more cancer cell colonization in the lung of HIF-2 α EC null mice (110). However, HIF-2 α inactivation from vascular endothelial (VE)-cadherin positive ECs decreased tumor growth in LLC and B16F1 models, as well as in carcinogen-induced skin epithelial tumors. HIF-2 α inactivation was shown to increase the number of vessels and their branching but decreasing the number of mature functional tumor vessels. This resulted from disrupted delta-like ligand 4/Notch (DII4/Notch) signaling leading to decreased expression of angiopoietin-2 (111, 112). These results show different roles for HIF-1 and HIF-2 in angiogenesis. Mice with PHD2 haplodeficiency in Tie2-positive ECs did not have an effect on the primary tumor growth, but the amount of liver metastases in a pancreatic cancer model was reduced. This resulted from HIF-2-induced expression of sVEGFR-1 and VE cadherin that normalized ECs with less permeable vessels leading to a less hypoxic tumor without any changes in the actual number of vessels (83, 95).

Pericytes are mural cells that cover the ECs and provide vascular stability and are known to signal to each other during angiogenesis (108). Pericyte depletion was shown to disrupt primary tumor growth by decreasing the microvessel density and increasing hypoxia, but this, however, led to increased metastasis showing their importance in tumor vasculature (113). Later, the increased hypoxia was shown to induce Ang-2 expression within the tumor which resulted in vascular instability and lung metastasis. This could be restored by inhibiting Ang-2 signaling (114).

HYPOXIC RESPONSE OF IMMUNE CELLS

The microenvironment of solid tumors also contains tumor infiltrating immune cells. These include lymphoid cells and myeloid cells, such as T- and B-cells and natural killer cells, TAMs, myeloid-derived suppressor cells (MDSCs), and neutrophils, which all have both pro- and antitumorigenic effects. Hypoxia has been shown to alter immune resistance and suppression, which helps tumor cells to survive immune surveillance (2). TAMs are the most common immune cells found within the tumor and are generally associated with tumor progression and also have been shown to promote cancer cell invasion and angiogenesis (115). Hypoxic tumor regions have been shown to recruit TAMs *via* VEGF and semaphoring 3A expression and once in a low oxygen condition their gene expression profile changes to a more cancer promoting phenotype (116, 117). Macrophages are known to have plasticity, and their phenotype can change based on external cues. Once they get activated they can have tumor suppressing M1 or tumor promoting M2 polarization. Stimulation driving the M1 phenotype also activates HIF-1 which upregulates iNOS levels and drives NO synthesis. During M2 polarization HIF-2 is induced leading to an increase in arginase-1, which in turn decreases the NO synthesis (118). *In vitro* assays suggest that depletion of HIF-1 α in TAMs induces more M2 phenotype (119). By using PHD2-haplodeficient mice, which ensured less hypoxic tumors, Laoui et al. showed, however, that the oxygenation state in

the tumor did not significantly affect the differentiation of TAMs into M1 or M2 like (120). They saw changes in hypoxia-regulated genes in M2 like TAMs, but not in M1 like TAMs. Overall the results suggest that hypoxia itself does not influence the activation of the TAMs into M1 nor M2 (120).

HIF-1 α - and HIF-2 α -expressing macrophages have been shown to promote tumor progression. Inactivation of HIF-1 α from lysozyme 2 (LysM)-positive neutrophils and macrophages in MMTV-PyMT mice led to hindered tumor progression and smaller tumors. This was shown to result from an increased number of cytotoxic T-cells (121). Mice lacking HIF-2 α from LysM-positive macrophages in inducible hepatocellular carcinoma and colitis-associated cancer had reduced number of TAMs in tumor regions which associated with a delayed tumor progression tendency (122). However, opposing results have been shown with PHD inactivation. One experiment showed that PHD2 inactivation in macrophages together with CD4⁺ T-cells decreased the tumor progression by overall downregulation of protumoral and antitumoral cytokines eventually leading to increased tumor cell death in an LLC model, and this was in part because of HIF-1 α stabilization (123). Mice with a melanoma tumor model were treated with granulocyte-macrophage colony-stimulating factor together with systemic inhibition of PHD3 by AKB-6899 leading to decreased tumor size and lung metastasis. This resulted from HIF-2 α stabilization in TAMs, which increased the expression of VEGF sequestering the soluble VEGFR-1 which decreased the vasculature within the tumor (124).

Hypoxia and HIF-1 α stabilization regulates the MDSCs within the tumor enhancing their role as T-cell suppressors (125). Tumor-infiltrating MDSCs, as well as macrophages and tumor cells, were shown to have increased levels of the cell surface protein PD-L1, which was shown to be an HIF-1 α target and upregulated by hypoxia. PD-L1 upregulation in MDSCs suppressed T-cell activation, whereas PD-L1 blockade under hypoxia enhanced MDSC-mediated T-cell proliferation and function and was associated with decreased interleukin-6 and interleukin-10 expression (68). Hypoxia has been shown to decrease the expression of the cell surface protein major histocompatibility complex class I *in vivo* and *in vitro* in renal cell carcinoma cells providing them a mechanism to evade immune surveillance by cytotoxic T-cells (126).

HYPOXIC RESPONSE OF THE ECM

In addition to the different cell types within the TME, the ECM composition and structure also contributes to tumor progression (94). The ECM does not only provide an architectural scaffold defining tissue boundaries but it also regulates cellular behavior, such as cell adhesion and migration by mechanical and biochemical cues. The ECM can bind and store growth factors or directly interact with receptors on the cell surfaces. The ECM is a dynamic meshwork of proteins that is constantly being remodeled and it is rich in proteoglycans and fibrillar collagens. ECM proteins have also been shown to directly induce cancer cell proliferation and metastasis. LOX is upregulated by hypoxia, and in a colorectal cancer model, LOX induced cancer

progression *via* activation of SRC signaling (127). The ECM is mainly secreted by CAFs as it is one of the main functions of fibroblast to maintain the homeostasis of the ECM. CAFs, however, have abnormal ECM regulation activity, and they have been shown to secrete more ECM proteins than normal fibroblasts (98). In addition to CAFs, cancer cells are known to play a part in ECM remodeling (128). A high collagen content together with a stiff ECM is generally associated with malignant metastatic cancers (75, 129). The biosynthesis of the fibrillar collagens requires posttranslational modifications that take place both inside and outside the cell with the help of collagen modifying enzymes, many of which are known to be regulated by HIF (130). Collagen modifying enzymes have been shown to have important roles in cancer progression. Inactivation of collagen prolyl 4-hydroxylase P4HA1 or P4HA2 in MDA-MB-123 breast cancer cells decreased collagen deposition and attenuated tumor growth and resulted in as much as 99% decrease in lung metastasis (79). Inactivation of lysyl hydroxylase PLOD2 in the same cancer model decreased the metastasis to lungs resulting from inefficient formation of collagen fibers and decreased tumor stiffness (78). Inhibiting LOX and lysyl oxidase-like 2 (LOXL2) and LOXL4 decreased metastasis in several cancer cell types (60, 74, 76). LOX, LOXL2, and LOXL4 deficiencies decreased collagen cross-linking and stiffness which was also needed to recruit CD11b⁺ BMDCs into the premetastatic niches to promote tumor cell colonization (60, 77, 80). LOXL2 in turn upregulated the expression of matrix remodeling enzymes such as tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 (MMP9) (76). LOXL2 also activated CAFs *via* integrin β 3 and promoted their collagen contraction, a phenomenon known to increase matrix stiffness (131).


Cancer-associated fibroblasts are able to mechanically remodel the ECM by active contraction resulting in matrix stiffening (105). CAFs with PHD2 haplodeficiency were less active than wild-type CAFs which was demonstrated by decreased expression levels of markers associated with CAFs (α SMA, FSP1, and PDGFR α) and decreased contraction capabilities (83). PHD2 haplodeficiency in CAFs also decreased matrix production, and this was accompanied by decreased expression of collagen modifying enzymes LOX, P4HA1, P4HA2, PLOD2 as well as matrix metalloproteinases MMP2 and MMP9. This is partly surprising, since hypoxic fibroblast and cancer cells generally upregulate the expression of the same genes (132). Similar results were seen with human head and neck carcinoma-associated fibroblasts and human vulvar carcinoma-associated fibroblasts. PHD2 inactivation or 1% oxygen decreased α SMA expression, and they had decreased contraction capabilities (104).

HYPOXIC RESPONSE OF CANCER METABOLISM

One of the most common characteristics for cancer cells is rapid proliferation, which is accompanied by high demands of energy. In normoxia, cells generally produce energy as ATP by mitochondrial oxidative phosphorylation, which is an O₂-dependent pathway. As tumors grow, cells face the limitation of decreased

oxygen concentration and switch to inefficient glycolysis to ensure ATP production (46). HIF-1 has been shown to be an important regulator in the metabolic switch as it induces the expression of genes that adjust the cellular metabolism away from oxidative phosphorylation toward increased glycolysis. This mechanism is not just to ensure the ATP production under hypoxia but also to prevent excessive formation of reactive oxygen species (ROS). Most importantly HIF-1 induces pyruvate dehydrogenase kinase 1 that inhibits the activity of the pyruvate dehydrogenase complex (PDC). PDC regulates the first step needed in oxidative phosphorylation where pyruvate is converted to acetyl coenzyme A (133). HIF-1 α also upregulates lactate dehydrogenase A and monocarboxylate transporter 4 which promotes conversion of pyruvate to lactate (end product of glycolysis) and transports it out of the cell, respectively (134, 135). HIF activation also upregulates the expression of glucose transporters GLUT1 and GLUT3, which are responsible for the glucose import into the cells (136, 137). Lactate from glycolysis is considered as a major reason for the tumor acidification. Hypoxia upregulates carbonic anhydrase IX, which regulates the tumor pH and has an important role in the survival of tumor cells in hypoxic regions of tumors and metastasis (138). In addition, HIF indirectly targets the metabolic genes that contribute to the glycolytic shift by upregulating miR-210. miR-210 in turn inhibits multiple targets such as iron-sulfur cluster assembly proteins (ISCU), cytochrome *c* oxidase assembly protein (COX10), NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 4 (NDUFA4), and succinate

dehydrogenase complex subunit D (SDHD), all of which play a role in mitochondrial function (139–141). PHD3 was in turn shown to induce the activity of PDC HIF independently by binding to the complex. PHD3 deficient cells were seen to have clear decreased PDC activity, which promoted survival in prolonged hypoxia together with a lower amount of ROS (142). HIF also suppresses mitochondrial function by downregulating multiple components in the electron transport chain and also by direct mitochondrial autophagy mediated by increased BCL2 interacting protein 3 (BNIP3) levels. In this way, hypoxia also decreases the levels of ROS, which are harmful in increased quantities (143). There are reports stating that mitochondrial ROS itself also regulates HIF, but there is also many opposing results [reviewed in Ref. (144)]. Increased ROS levels have been shown to promote HIF stabilization during hypoxia, by further inhibiting PHD enzymes. Contradicting results claim it is not ROS regulating HIF stabilization, but rather the mitochondria, which monitor the intracellular oxygen availability. Under normoxic conditions ROS are able to stabilize HIF, but the exact mechanism is not clear. It has been suggested to be *via* inhibition of PHDs or pVHL, but another signaling pathway has been proposed. HIF-1 α gene expression was shown to be upregulated in oral squamous cell carcinoma and MCF-7 breast cancer cells by ROS *via* induced ERK and P13K/AKT signaling (145, 146). Overall, HIF-regulated glucose metabolism supplies sufficient glucose import for less efficient glycolysis and removes the excess end products out of the cell. It defends the cells against increased



ROS production, which is generated in the oxidative phosphorylation pathway under too low oxygen concentration and gives the cancer cells protection to proliferate and grow under hypoxic conditions (147).

Within the solid tumor there are regions that are not under hypoxia, but still the cancer cells have a tendency to switch to inefficient glycolysis even in presence of oxygen. However, the metabolic state in the different cells within the tumor is heterogeneous and there has been evidence of supplying metabolites between cells (148). When fibroblasts become CAFs, they have been shown to decrease the expression of isocitrate dehydrogenase 3 α . This leads to a decreased amount of effective 2-oxoglutarate, which is needed as a co-substrate in the hydroxylation reaction, and increasing levels of succinate and fumarate. This results to PHD inhibition, which stabilizes HIF-1 α and promotes glycolysis in the CAFs. Metabolites from the normoxic glycolysis in CAFs was hypothesized to feed the surrounding cancer cells (149).

CONCLUSION AND FUTURE PERSPECTIVES

Hypoxia is a condition that plays a role in normal physiology, such as during embryonic development, but it is more commonly associated with pathological states. Oxygen deprivation is a common feature of all solid tumors and affects all components of the TME (Figure 2). Hypoxia has clear effects on both cancer cells and surrounding stromal cells, but it does not promote tumor progression in every case. Different cell types seem to be differentially regulated by the hypoxic environment. In cancer cells, HIF stabilization generally promotes tumor progression. Inactivation of HIF-1 or HIF-2 in cancer cells in mouse cancer models decreases the tumor growth and the formation of metastases in many ways, practically affecting all the hallmarks of cancer.

REFERENCES

- Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. *Cancer Metastasis Rev* (2007) 26:225–39. doi:10.1007/s10555-007-9055-1
- LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. *Nat Cell Biol* (2016) 18:356–65. doi:10.1038/ncb3330
- Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* (2012) 21:309–22. doi:10.1016/j.ccr.2012.02.022
- Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. *Trends Cancer* (2016) 2:758–70. doi:10.1016/j.trecan.2016.10.016
- Span PN, Bussink J. Biology of hypoxia. *Semin Nucl Med* (2015) 45:101–9. doi:10.1053/j.semnuclmed.2014.10.002
- Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. *Nat Rev Cancer* (2008) 8:851–64. doi:10.1038/nrc2501
- Giampietri C, Petrunaro S, Conti S, Facchiano A, Filippini A, Ziparo E. Cancer microenvironment and endoplasmic reticulum stress response. *Mediators Inflamm* (2015) 2015:417281. doi:10.1155/2015/417281
- Pereira ER, Frudd K, Awad W, Hendershot LM. Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF). *J Biol Chem* (2014) 289:3352–64. doi:10.1074/jbc.M113.507194

When cancer cells are targeted with PHD2 inactivation, which enables HIF stabilization, the results are more variable. PHD enzymes do also have HIF-independent targets and functions that can complicate their role in cancer promotion. However, PHD2 haplodeficiency in ECs leads to less tumor hypoxia resulting from HIF-2 activation in the ECs themselves stimulating EC intrinsic proangiogenic signaling leading to EC normalization. Global haplodeficient inactivation of PHD2 or treatment with a PHD inhibitor does not have an effect on primary tumor growth, but it rather decreases metastasis. Targeting PHD2 in CAFs leads to their deactivation and reduces their capabilities to promote cancer cell invasion and metastasis both *in vitro* and *in vivo*. These findings suggest that global targeting of PHD and HIF activities is sufficient to reprogramme the TME to suppress tumor progression. However, we are only beginning to understand how hypoxia, HIFs and PHDs alter the TME, and further research is required to gain insight. Thus, while hypoxia research has been performed for decades, recent data suggests that there is much more to learn, and that this may have important clinical implications regarding the use of agents that target hypoxia pathways such as HIF or PHD inhibitors.

AUTHOR CONTRIBUTIONS

The review was written by AL and edited by JTE.

ACKNOWLEDGMENTS

We would like to thank Kamilla Westarp Zornhagen for the helpful comments for the manuscript. We thank the KBVU grant (R146-A9250) from the Danish Cancer Society that supports AL and the Novo Nordisk Foundation for the Hallas Møller Stipendium that supports JTE.

- Vanacker H, Velters J, Moudombi L, Caux C, Janssens S, Michallet M-C. Emerging role of the unfolded protein response in tumor immunosurveillance. *Trends Cancer* (2017) 3:491–505. doi:10.1016/j.trecan.2017.05.005
- Xu K, Liu P, Wei W. mTOR signaling in tumorigenesis. *Biochim Biophys Acta* (2014) 1846:638–54. doi:10.1016/j.bbcan.2014.10.007
- Heberle AM, Prentzell MT, van Eunen K, Bakker BM, Grelleisch SN, Thedieck K. Molecular mechanisms of mTOR regulation by stress. *Mol Cell Oncol* (2015) 2:e970489. doi:10.4161/23723548.2014.970489
- Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. *J Biol Chem* (2003) 278:29655–60. doi:10.1074/jbc.M212770200
- Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. *Mol Cell Biol* (2002) 22:2283–93. doi:10.1128/MCB.22.7.2283-2293.2002
- Wolff NC, Vega-Rubin-de-Celis S, Xie X-J, Castrillon DH, Kabbani W, Brugarolas J. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. *Mol Cell Biol* (2011) 31:1870–84. doi:10.1128/MCB.01393-10
- Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. *Proc Natl Acad Sci U S A* (2010) 107:18892–7. doi:10.1073/pnas.1004952107
- Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR. mTORC1 drives HIF-1 α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. *Oncogene* (2015) 34:2239–50. doi:10.1038/onc.2014.164

17. Al-Ansari MM, Hendrayani S-F, Tulbah A, Al-Tweigeri T, Shehata AI, Aboussekhra A. p16INK4A represses breast stromal fibroblasts migration/invasion and their VEGF-A-dependent promotion of angiogenesis through Akt inhibition. *Neoplasia* (2012) 14:1269–77. doi:10.1593/neo.121632
18. Ivan M, Kondo K, Yang H, Kim W, Valiano J, Ohm M, et al. HIF1 α targeted for VHL-mediated destruction by proline hydroxylation: implications for O₂ sensing. *Science* (2001) 292:464–8. doi:10.1126/science.1059817
19. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-1 α to the von Hippel-Lindau ubiquitylation complex by O₂-regulated prolyl hydroxylation. *Science* (2001) 292:468–72. doi:10.1126/science.1059796
20. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-1 α chains activated by prolyl hydroxylation. *EMBO J* (2001) 20:5197–206. doi:10.1093/emboj/20.18.5197
21. Yu F, White SB, Zhao Q, Lee FS. HIF-1 α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. *Proc Natl Acad Sci U S A* (2001) 98:9630–5. doi:10.1073/pnas.181341498
22. Hu C-J, Sataur A, Wang L, Chen H, Simon MC. The N-terminal trans-activation domain confers target gene specificity of hypoxia-inducible factors HIF-1 α and HIF-2 α . *Mol Biol Cell* (2007) 18:4528–42. doi:10.1091/mbc.e06-05-0419
23. Heikkilä M, Pasanen A, Kivirikko KI, Myllyharju J. Roles of the human hypoxia-inducible factor (HIF)-1 α variants in the hypoxia response. *Cell Mol Life Sci* (2011) 68:3885–901. doi:10.1007/s00018-011-0679-5
24. Makino Y, Uenishi R, Okamoto K, Isoe T, Hosono O, Tanaka H, et al. Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. *J Biol Chem* (2007) 282:14073–82. doi:10.1074/jbc.M700732200
25. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. *Science* (2001) 294:1337–40. doi:10.1126/science.1066373
26. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. *Cell* (2001) 107:43–54. doi:10.1016/S0092-8674(01)00507-4
27. Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1 α . *Cancer Res* (2006) 66:3688–98. doi:10.1158/0008-5472.CAN-05-4564
28. Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. *J Biol Chem* (2003) 278:30772–80. doi:10.1074/jbc.M304982200
29. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 α in normoxia. *EMBO J* (2003) 22:4082–90. doi:10.1093/emboj/cdg392
30. Takeda K, Ho VC, Takeda H, Duan L-J, Nagy A, Fong G-H. Placental but not heart defects are associated with elevated hypoxia-inducible factor 1 α levels in mice lacking prolyl hydroxylase domain protein 2. *Mol Cell Biol* (2006) 26:8336–46. doi:10.1128/MCB.00425-06
31. Appelhoff RJ, Tian Y-M, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. *J Biol Chem* (2004) 279:38458–65. doi:10.1074/jbc.M406026200
32. Aprelikova O, Chandramouli GVR, Wood M, Vasselli JR, Riss J, Maranchie JK, et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. *J Cell Biochem* (2004) 92:491–501. doi:10.1002/jcb.20067
33. To KKW, Huang LE. Suppression of hypoxia-inducible factor 1 α (HIF-1 α) transcriptional activity by the HIF prolyl hydroxylase EGLN1. *J Biol Chem* (2005) 280:38102–7. doi:10.1074/jbc.M504342200
34. Guo J, Chakraborty AA, Liu P, Gan W, Zheng X, Inuzuka H, et al. pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. *Science* (2016) 353:929–32. doi:10.1126/science.aad5755
35. Hiwatashi Y, Kanno K, Takasaki C, Goryo K, Sato T, Torii S, et al. PHD1 interacts with ATF4 and negatively regulates its transcriptional activity without prolyl hydroxylation. *Exp Cell Res* (2011) 317:2789–99. doi:10.1016/j.yexcr.2011.09.005
36. Köditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C, et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. *Blood* (2007) 110:3610–7. doi:10.1182/blood-2007-06-094441
37. Schlisio S, Kenchappa RS, Vredeveld LCW, George RE, Stewart R, Greulich H, et al. The kinesin KIF1B β acts downstream from EglN3 to induce apoptosis and is a potential p36 tumor suppressor. *Genes Dev* (2008) 22:884–93. doi:10.1101/gad.1648608
38. Xie L, Pi X, Mishra A, Fong G, Peng J, Patterson C. PHD3-dependent hydroxylation of HCLK2 promotes the DNA damage response. *J Clin Invest* (2012) 122:2827–36. doi:10.1172/JCI62374
39. Xie L, Xiao K, Whalen EJ, Forrester MT, Freeman RS, Fong G, et al. Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. *Sci Signal* (2009) 2:ra33. doi:10.1126/scisignal.2000444
40. Yang M, Su H, Soga T, Kranc KR, Pollard PJ. Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism. *Hypoxia (Auckl)* (2014) 2:127–42. doi:10.2147/HP.S47968
41. Rankin EB, Nam J-M, Giaccia AJ. Hypoxia: signaling the metastatic cascade. *Trends Cancer* (2016) 2:295–304. doi:10.1016/j.trecan.2016.05.006
42. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. *Cancer Metab* (2014) 2:3. doi:10.1186/2049-3002-2-3
43. Tarade D, Ohm M. The HIF and other quandaries in VHL disease. *Oncogene* (2018) 37:139–47. doi:10.1038/onc.2017.338
44. Pore N, Jiang Z, Shu H-K, Bernhard E, Kao GD, Maity A. Akt1 activation can augment hypoxia-inducible factor-1 α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. *Mol Cancer Res* (2006) 4:471–9. doi:10.1158/1541-7786.MCR-05-0234
45. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. *J Biol Chem* (2003) 278:14013–9. doi:10.1074/jbc.M209702200
46. Nguyen TL, Durán RV. Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism. *Int J Biochem Cell Biol* (2016) 80:71–80. doi:10.1016/j.biocel.2016.09.026
47. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1 α in tumours which result from germline FH and SDH mutations. *Hum Mol Genet* (2005) 14:2231–9. doi:10.1093/hmg/ddi227
48. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung Y-L, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. *Cancer Cell* (2005) 8:143–53. doi:10.1016/j.ccr.2005.06.017
49. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-1 α prolyl hydroxylase. *Cancer Cell* (2005) 7:77–85. doi:10.1016/j.ccr.2004.11.022
50. Zeng L, Morinibu A, Kobayashi M, Zhu Y, Wang X, Goto Y, et al. Aberrant IDH3 α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis. *Oncogene* (2015) 34:4758–66. doi:10.1038/onc.2014.411
51. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* (2012) 483:484–8. doi:10.1038/nature10898
52. Burr SP, Costa ASH, Grice GL, Timms RT, Lobb IT, Freisinger P, et al. Mitochondrial protein lipoylation and the 2-oxoglutarate dehydrogenase complex controls HIF1 α stability in aerobic conditions. *Cell Metab* (2016) 24:740–52. doi:10.1016/j.cmet.2016.09.015
53. Tarhonskaya H, Ryzdik AM, Leung IKH, Loik ND, Chan MC, Kawamura A, et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. *Nat Commun* (2014) 5:3423. doi:10.1038/ncomms4423
54. Briggs KJ, Koivunen P, Cao S, Backus KM, Olenchok BA, Patel H, et al. Paracrine induction of HIF by glutamate in breast cancer: eglN1 senses cysteine. *Cell* (2016) 166:126–39. doi:10.1016/j.cell.2016.05.042
55. Colegio OR, Chu N-Q, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature* (2014) 513:559–63. doi:10.1038/nature13490
56. Schito L, Rey S, Tafani M, Zhang H, Wong CC-L, Russo A, et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B

- promotes lymphatic metastasis of hypoxic breast cancer cells. *Proc Natl Acad Sci U S A* (2012) 109:E2707–16. doi:10.1073/pnas.1214019109
57. Zhang H, Wong CCL, Wei H, Gilkes DM, Korangath P, Chaturvedi P, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. *Oncogene* (2012) 31:1757–70. doi:10.1038/ncr.2011.365
 58. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1 α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. *Cancer Res* (2007) 67:563–72. doi:10.1158/0008-5472.CAN-06-2701
 59. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, et al. Hypoxia-inducible factor 1 α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. *Breast Cancer Res* (2012) 14:R6. doi:10.1186/bcr3087
 60. Wong CC-L, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. *Proc Natl Acad Sci U S A* (2011) 108:16369–74. doi:10.1073/pnas.1113483108
 61. Wong CC-L, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. *J Mol Med* (2012) 90:803–15. doi:10.1007/s00109-011-0855-y
 62. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. *Cancer Res* (2007) 67:4157–63. doi:10.1158/0008-5472.CAN-06-2355
 63. Dunn LK, Mohammad KS, Fournier PGJ, McKenna CR, Davis HW, Niewolna M, et al. Hypoxia and TGF- β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. *PLoS One* (2009) 4:e6896. doi:10.1371/journal.pone.0006896
 64. Keith B, Johnson RS, Simon MC. HIF1 α and HIF2 α : sibling rivalry in hypoxic tumour growth and progression. *Nat Rev Cancer* (2011) 12:9–22. doi:10.1038/nrc3183
 65. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. *Trends Pharmacol Sci* (2012) 33:207–14. doi:10.1016/j.tips.2012.01.005
 66. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. *Mol Cell Biol* (2004) 24:2875–89. doi:10.1128/MCB.24.7.2875-2889.2004
 67. Peng X-H, Karna P, Cao Z, Jiang B-H, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. *J Biol Chem* (2006) 281:25903–14. doi:10.1074/jbc.M603414200
 68. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1 α , and its blockade under hypoxia enhanced MDSC-mediated T cell activation. *J Exp Med* (2014) 211:781–90. doi:10.1084/jem.20131916
 69. Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. *Proc Natl Acad Sci U S A* (2015) 112:E6215–23. doi:10.1073/pnas.1520032112
 70. Nallamshetty S, Chan SY, Loscalzo J. Hypoxia: a master regulator of microRNA biogenesis and activity. *Free Radic Biol Med* (2013) 64:20–30. doi:10.1016/j.freeradbiomed.2013.05.022
 71. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, et al. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. *Cancer Res* (2012) 72:4629–41. doi:10.1158/0008-5472.CAN-12-1383
 72. Yang Y, Zhang J, Xia T, Li G, Tian T, Wang M, et al. MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma. *Oncol Rep* (2016) 36:2553–62. doi:10.3892/or.2016.5129
 73. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. *Proc Natl Acad Sci U S A* (2008) 105:6392–7. doi:10.1073/pnas.0802047105
 74. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le Q-T, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature* (2006) 440:1222–6. doi:10.1038/nature04695
 75. Levental KR, Yu H, Kass L, Lalkins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell* (2009) 139:891–906. doi:10.1016/j.cell.2009.10.027
 76. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. *Cancer Res* (2011) 71:1561–72. doi:10.1158/0008-5472.CAN-10-2868
 77. Cox TR, Bird D, Baker A-M, Barker HE, Ho MW-Y, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. *Cancer Res* (2013) 73:1721–32. doi:10.1158/0008-5472.CAN-12-2233
 78. Gilkes DM, Bajpai S, Wong CC, Chaturvedi P, Hubbi ME, Wirtz D, et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. *Mol Cancer Res* (2013) 11:456–66. doi:10.1158/1541-7786.MCR-12-0629
 79. Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, et al. Collagen prolyl hydroxylases are essential for breast cancer metastasis. *Cancer Res* (2013) 73:3285–96. doi:10.1158/0008-5472.CAN-12-3963
 80. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. *Cancer Cell* (2009) 15:35–44. doi:10.1016/j.ccr.2008.11.012
 81. Peng G, Liu Y. Hypoxia-inducible factors in cancer stem cells and inflammation. *Trends Pharmacol Sci* (2015) 36:374–83. doi:10.1016/j.tips.2015.03.003
 82. Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, et al. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. *Nat Cell Biol* (2017) 19:120–32. doi:10.1038/ncb3465
 83. Kuchnio A, Moens S, Bruning U, Kuchnio K, Cruys B, Thienpont B, et al. The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts. *Cell Rep* (2015) 12:992–1005. doi:10.1016/j.celrep.2015.07.010
 84. Wottawa M, Leisering P, von Ahlen M, Schnelle M, Vogel S, Malz C, et al. Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF- β 1 processing. *Int J Cancer* (2013) 132:2787–98. doi:10.1002/ijc.27982
 85. Bordoli MR, Stiehl DP, Borsig L, Kristiansen G, Hausladen S, Schraml P, et al. Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis. *Oncogene* (2011) 30:548–60. doi:10.1038/ncr.2010.433
 86. Chan DA, Kawahara TLA, Sutphin PD, Chang HY, Chi J-T, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. *Cancer Cell* (2009) 15:527–38. doi:10.1016/j.ccr.2009.04.010
 87. Klotzsche-von Ameln A, Muschter A, Mamlouk S, Kalucka J, Prade I, Franke K, et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGF β . *Cancer Res* (2011) 71:3306–16. doi:10.1158/0008-5472.CAN-10-3838
 88. Klotzsche-von Ameln A, Muschter A, Heimesaat MM, Breier G, Wielockx B. HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGF β activation. *Cancer Biol Ther* (2012) 13:216–23. doi:10.4161/cbt.13.4.18830
 89. Su Y, Loos M, Giese N, Metzger E, Büchler MW, Friess H, et al. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. *Cancer* (2012) 118:960–72. doi:10.1002/cncr.26344
 90. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung H-W, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. *Cancer Cell* (2009) 16:413–24. doi:10.1016/j.ccr.2009.09.029
 91. Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, et al. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. *Genes Dev* (2014) 28:1429–44. doi:10.1101/gad.242131.114
 92. Deschoemaeker S, Di Conza G, Lilla S, Martín-Pérez R, Mennerich D, Boon L, et al. PHD1 regulates p53-mediated colorectal cancer chemoresistance. *EMBO Mol Med* (2015) 7:1350–65. doi:10.15252/emmm.201505492
 93. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. *Nat Med* (2013) 19:1423–37. doi:10.1038/nm.3394

94. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of tumor micro-environment in tumorigenesis. *J Cancer* (2017) 8:761–73. doi:10.7150/jca.17648
95. Mazzone M, Dettori D, de Oliveira RL, Loges S, Schmidt T, Jonckx B, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell* (2009) 136:839–51. doi:10.1016/j.cell.2009.01.020
96. Kalluri R. The biology and function of fibroblasts in cancer. *Nat Rev Cancer* (2016) 16:582–98. doi:10.1038/nrc.2016.73
97. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell* (2005) 121:335–48. doi:10.1016/j.cell.2005.02.034
98. Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. *Biochem Soc Trans* (2017) 45:229–36. doi:10.1042/BST20160387
99. Kuzet S-E, Gaggioli C. Fibroblast activation in cancer: when seed fertilizes soil. *Cell Tissue Res* (2016) 365:607–19. doi:10.1007/s00441-016-2467-x
100. Kim J, Evans C, Weidemann A, Takeda N, Lee YS, Stockmann C, et al. Loss of fibroblast HIF-1 α accelerates tumorigenesis. *Cancer Res* (2012) 72:3187–95. doi:10.1158/0008-5472.CAN-12-0534
101. De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggolini M. HIF-1 α /GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). *Breast Cancer Res* (2013) 15:R64. doi:10.1186/bcr3458
102. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, et al. HIF1- α functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. *Cell Cycle* (2010) 9:3534–51. doi:10.4161/cc.9.17.12908
103. Chiavarina B, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Tanowitz HB, Pestell RG, et al. Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1 α and HIF2 α in tumor-associated fibroblasts and human breast cancer cells. *Cell Cycle* (2012) 11:3280–9. doi:10.4161/cc.21643
104. Madsen CD, Pedersen JT, Venning FA, Singh LB, Moeendarbary E, Charras G, et al. Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. *EMBO Rep* (2015) 16:1394–408. doi:10.15252/embr.201540107
105. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. *Nat Cell Biol* (2013) 15:637–46. doi:10.1038/ncb2756
106. Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. *Pharmacol Ther* (2015) 153:107–24. doi:10.1016/j.pharmthera.2015.06.006
107. Baker A-M, Bird D, Welti JC, Gourlaouen M, Lang G, Murray GI, et al. Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. *Cancer Res* (2013) 73:583–94. doi:10.1158/0008-5472.CAN-12-2447
108. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov* (2011) 10:417–27. doi:10.1038/nrd3455
109. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber H-P, et al. Loss of HIF-1 α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. *Cancer Cell* (2004) 6:485–95. doi:10.1016/j.ccr.2004.09.026
110. Branco-Price C, Zhang N, Schnelle M, Evans C, Katschinski DM, Liao D, et al. Endothelial cell HIF-1 α and HIF-2 α differentially regulate metastatic success. *Cancer Cell* (2012) 21:52–65. doi:10.1016/j.ccr.2011.11.017
111. Skuli N, Liu L, Runge A, Wang T, Yuan L, Patel S, et al. Endothelial deletion of hypoxia-inducible factor-2 α (HIF-2 α) alters vascular function and tumor angiogenesis. *Blood* (2009) 114:469–77. doi:10.1182/blood-2008-12-193581
112. Skuli N, Majmudar AJ, Krock BL, Mesquita RC, Mathew LK, Quinn ZL, et al. Endothelial HIF-2 α regulates murine pathological angiogenesis and revascularization processes. *J Clin Invest* (2012) 122:1427–43. doi:10.1172/JCI57322
113. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. *Cancer Cell* (2012) 21:66–81. doi:10.1016/j.ccr.2011.11.024
114. Keskin D, Kim J, Cooke VG, Wu C-C, Sugimoto H, Gu C, et al. Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. *Cell Rep* (2015) 10:1066–81. doi:10.1016/j.celrep.2015.01.035
115. Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. *Mediators Inflamm* (2017) 2017:9624760. doi:10.1155/2017/9624760
116. Du R, Lu KV, Petrutsch C, Liu P, Ganss R, Passequé E, et al. HIF1 α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. *Cancer Cell* (2008) 13:206–20. doi:10.1016/j.ccr.2008.01.034
117. Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. *Cancer Cell* (2013) 24:695–709. doi:10.1016/j.ccr.2013.11.007
118. Takeda N, O'Dea EL, Doedens A, Kim J, Weidemann A, Stockmann C, et al. Differential activation and antagonistic function of HIF-1 α isoforms in macrophages are essential for NO homeostasis. *Genes Dev* (2010) 24:491–501. doi:10.1101/gad.1881410
119. Werno C, Menrad H, Weigert A, Dehne N, Goerdts S, Schledzewski K, et al. Knockout of HIF-1 α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. *Carcinogenesis* (2010) 31:1863–72. doi:10.1093/carcin/bgg088
120. Laoui D, Van Overmeire E, Di Conza G, Aldeni C, Keirsse J, Morias Y, et al. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. *Cancer Res* (2014) 74:24–30. doi:10.1158/0008-5472.CAN-13-1196
121. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, et al. Macrophage expression of hypoxia-inducible factor-1 α suppresses T-cell function and promotes tumor progression. *Cancer Res* (2010) 70:7465–75. doi:10.1158/0008-5472.CAN-10-1439
122. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan L-J, et al. Hypoxia-inducible factor 2 α regulates macrophage function in mouse models of acute and tumor inflammation. *J Clin Invest* (2010) 120:2699–714. doi:10.1172/JCI39506
123. Mamlouk S, Kalucka J, Singh RP, Franke K, Muschter A, Langer A, et al. Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. *Int J Cancer* (2014) 134:849–58. doi:10.1002/ijc.28409
124. Roda JM, Wang Y, Sumner LA, Phillips GS, Marsh CB, Eubank TD. Stabilization of HIF-2 α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. *J Immunol* (2012) 189:3168–77. doi:10.4049/jimmunol.1103817
125. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J-I, Cheng P, et al. HIF-1 α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. *J Exp Med* (2010) 207:2439–53. doi:10.1084/jem.20100587
126. Sethumadhavan S, Silva M, Philbrook P, Nguyen T, Hatfield SM, Ohta A, et al. Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells. *PLoS One* (2017) 12:e0187314. doi:10.1371/journal.pone.0187314
127. Baker A-M, Cox TR, Bird D, Lang G, Murray GI, Sun X-F, et al. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. *J Natl Cancer Inst* (2011) 103:407–24. doi:10.1093/jnci/djq569
128. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. *J Cell Biol* (2012) 196:395–406. doi:10.1083/jcb.201102147
129. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. *BMC Med* (2008) 6:11. doi:10.1186/1741-7015-6-11
130. Myllyharju J, Schipani E. Extracellular matrix genes as hypoxia-inducible targets. *Cell Tissue Res* (2010) 339:19–29. doi:10.1007/s00441-009-0841-7
131. Barker HE, Bird D, Lang G, Erler JT. Tumor-secreted LOXL2 activates fibroblasts through FAK signaling. *Mol Cancer Res* (2013) 11:1425–36. doi:10.1158/1541-7786.MCR-13-0033-T
132. Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic

- conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. *J Biol Chem* (2013) 288:10819–29. doi:10.1074/jbc.M112.442939
133. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. *J Biol Chem* (1996) 271:32529–37. doi:10.1074/jbc.271.51.32529
 134. Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metab* (2006) 3:177–85. doi:10.1016/j.cmet.2006.02.002
 135. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab* (2006) 3:187–97. doi:10.1016/j.cmet.2006.01.012
 136. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. *Proc Natl Acad Sci U S A* (1997) 94:8104–9. doi:10.1073/pnas.94.15.8104
 137. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. *J Biol Chem* (2001) 276:9519–25. doi:10.1074/jbc.M010144200
 138. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. *Cancer Res* (2011) 71:3364–76. doi:10.1158/0008-5472.CAN-10-4261
 139. Chan SY, Zhang Y-Y, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. *Cell Metab* (2009) 10:273–84. doi:10.1016/j.cmet.2009.08.015
 140. Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. *Oncogene* (2010) 29:4362–8. doi:10.1038/onc.2010.193
 141. Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. *Cell Death Differ* (2011) 18:465–78. doi:10.1038/cdd.2010.119
 142. Kikuchi D, Minamishima YA, Nakayama K. Prolyl-hydroxylase PHD3 interacts with pyruvate dehydrogenase (PDH)-E1 β and regulates the cellular PDH activity. *Biochem Biophys Res Commun* (2014) 451:288–94. doi:10.1016/j.bbrc.2014.07.114
 143. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. *J Biol Chem* (2008) 283:10892–903. doi:10.1074/jbc.M800102200
 144. Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1 α by reactive oxygen species: new developments in an old debate. *J Cell Biochem* (2015) 116:696–703. doi:10.1002/jcb.25074
 145. Sasabe E, Yang Z, Ohno S, Yamamoto T. Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1 α expression in oral squamous cell carcinoma cells. *Free Radic Biol Med* (2010) 48:1321–9. doi:10.1016/j.freeradbiomed.2010.02.013
 146. Du J, Xu R, Hu Z, Tian Y, Zhu Y, Gu L, et al. PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1 α expression in MCF-7 breast cancer cells. *PLoS One* (2011) 6:e25213. doi:10.1371/journal.pone.0025213
 147. Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. *EMBO J* (2017) 36:252–9. doi:10.15252/embj.201695204
 148. Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor micro-environment. *Trends Cell Biol* (2017) 27:863–75. doi:10.1016/j.tcb.2017.06.003
 149. Zhang D, Wang Y, Shi Z, Liu J, Sun P, Hou X, et al. Metabolic reprogramming of cancer-associated fibroblasts by IDH3 α downregulation. *Cell Rep* (2015) 10:1335–48. doi:10.1016/j.celrep.2015.02.006

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Laitala and Erler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.